Drug Profile
Tariquidar
Alternative Names: XR 9576Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Xenova Group
- Developer QLT
- Class Antineoplastics; Quinolines; Small molecules
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer
Most Recent Events
- 03 Mar 2005 Phase-II clinical trials in Adrenal cancer in USA (IV)
- 03 Mar 2005 Phase-II clinical trials in Cervical cancer in USA (IV)
- 03 Mar 2005 Phase-II clinical trials in Non-small cell lung cancer in North America (IV)